Biotech Sector Turns Red-Hot on Alzheimer’s Treatment News In Phase 3 trials, a Biogen / Eisai Alzheimer’s drug slowed cognitive decline by 27%. 8 MIN READ 10.23.2022
Big Pharma and The Need for Speed Bayer is spending over $2B in the next 2.5 years to upgrade its manufacturing and supply chain. 4 MIN READ 10.16.2022
Biogen CEO Michel Vounatsos To Step Down After Commercial Failure of Alzheimer’s Drug Biogen will also halt marketing of Aduhelm. 2 MIN READ 05.4.2022
Editas Medicine Names Gilmore O’Neill as CEO O'Neill was most recently chief medical officer at Sarepta Therapeutics. 2 MIN READ 04.14.2022
Voyager Therapeutics Names Alfred Sandrock as CEO, Former Biogen R&D Head Sandrock spent 23 years at Biogen, where he was head of R&D and chief medical officer. 2 MIN READ 03.24.2022
FDA Narrows Prescribing Instructions for Biogen’s Controversial Alzheimer’s Drug The FDA has faced an intense public backlash since its approval of Aduhelm (aducanumab) last month. 4 MIN READ 07.8.2021
